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Cytotoxic T lymphocytes (CTL) are important for controlling equine infectious anemia virus (EIAV). Because Gag matrix (MA) and
capsid (CA) are the most frequently recognized proteins, the hypothesis that CTL from EIAV-infected horses with diverse MHC class I alleles
recognize epitope clusters (EC) in these proteins was tested. Four EC were identified by CTL from 15 horses and 8 of these horses had
diverse MHC class I alleles. Two of the eight had CTL to EC1, six to EC2, five to EC3, and four to EC4. Because EC2–4 were recognized by
CTL from N50% of horses with diverse alleles, the hypothesis was accepted. EC1 and EC3 were the most conserved EC and these more
conserved broadly recognized EC may be most useful for CTL induction, helping overcome MHC class I polymorphism and antigenic
variation.
D 2004 Elsevier Inc. All rights reserved.
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Equine infectious anemia virus (EIAV), a lentivirus,
causes persistent infection in horses that is initially charac-
terized by recurrent viremia with fever, thrombocytopenia,
and anemia within the first 6–12 months of infection (Sellon
et al., 1994). Disease episodes are associated with viral
antigenic variants as defined by neutralizing antibody (Kono
et al., 1973; Rwambo et al., 1990a) and, recently, by cytotoxic
T lymphocytes (CTL) (Mealey et al., 2003). Immune
responses to EIAV are critical for termination of the initial
viremia, as shown by comparison of viremia between normal
and severe combined immunodeficient (SCID) foals which
lack functional T and B lymphocytes (Perryman et al., 1988).
In addition, adoptive transfer of immune lymphocytes to an
EIAV-infected SCID foal prevented continuous EIAV repli-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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infected horses are eventually controlled and a lifelong
carrier stage follows (Coggins, 1984). The mechanism used
to control viremia during the carrier stage in EIAV-infected
horses is not clear, but protective immune responses likely
include neutralizing antibody and CTL (Hammond et al.,
1997, 2000; Kono, 1969; Kono et al., 1970; Perryman et al.,
1988; Zhang et al., 1998). The ability of horses to restrict
plasma viremia to a very low level after a few disease
episodes and become lifelong carriers provides an oppor-
tunity to define protective immune responses to a natural
lentiviral infection.
CTL are critical for control of lentiviruses including
EIAV. In EIAV, clearance of initial plasma viremia is
associated with the presence of CTL (Hammond et al.,
1997; McGuire et al., 1994) and occurs before the appea-
rance of neutralizing antibody (Carpenter et al., 1987;
Montelaro et al., 1984; O’Rourke et al., 1988). In addition,
individual vaccinates in immunization trials were protected
against homologous viral infection in the absence of
detectable neutralizing antibody at the time of challenge04) 144–154
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responses correlate with virus clearance (Kuroda et al.,
1999; Ogg et al., 1998). Eliminating CD8+ cells from
monkeys during chronic SIV infection resulted in a rapid
and marked increase in viremia that was again suppressed
coincident with the reappearance of SIV-specific CD8+ T
lymphocytes (Schmitz et al., 1999). This result demonstrates
that CD8+ cells are necessary for controlling lentivirus
infection and supports vaccine approaches that elicit CD8+
T lymphocytes.
Induction of effective CTL responses to lentiviruses is
complicated by variation of CTL epitopes (Goulder et al.,
2001; Kaur et al., 2001; Mealey et al., 2003; Zhang et al.,
1999) and MHC class I polymorphism (Bailey et al.,
2000; Bernoco et al., 1987; Ellis et al., 1995; Evans et
al., 1999; Lazary et al., 1988). A comprehensive, yet
difficult strategy, to overcome these complications is to
use epitopes from multiple proteins from multiple viral
variants presented by different MHC class I alleles to
induce protective CTL responses. An easier approach is
suggested in a report describing relatively conserved
overlapping HIV-1 epitopes recognized by CTL from
several individuals (Buseyne et al., 1993; Goulder et al.,
2000a, 2000b; Wilson et al., 1997). One study of HIV-1-
infected patients found three dominant CTL epitope
clusters (EC) in Gag p17 [matrix (MA)] and p24 [capsid
(CA)] that were recognized irrespective of the virus clade,
ethnicity, or age group studied (Goulder et al., 2000a).
However, those EC were defined with CTL from
individuals that shared some MHC class I alleles (Goulder
et al., 2000a). Therefore, EC need to be evaluated inTable 1
Recognition of Gag EC by CTL from 17 EIAV-infected horses
Horse no. MHC class I haplotype
Alleles identified
by sequencing
(Chung et al., 2003)
ELA-A type
A2147 7-1, 7-4 A4a
A2150 104, 105, 106, 141 A1/W11
H593 113, 114 A1a
H596 115, 116, 117, 118, 119 A4/W11
H610 111, 121, 122 A6a
H614 123, 124, 125, 126, 127 A9a
H629 Not done A3/A5
H631 133, 134, 135, 136 Undetermined
A2140 Not done A1/W11
H601 Not done A1/W11
H507c Not done A7/W11
H513c Not done A5/A8
H521c Not done A1/W11
H529c Not done A1/A5
H532c Not done A5/A6
H540 109, 111 A5/A6
A2153 107, 7-1, 7-4 A4a
a Only one ELA-A type was detected with the antisera used (A1-A10 and W11)
b Undetermined indicates that none of the available antisera reacted with lympho
c Gag epitope mapping with CTL from these five horses was previously reportedindividuals with more heterologous MHC class I alleles to
determine if they could be used to induce broadly reactive
CTL responses in populations with diverse MHC class I
haplotypes.
Studies of CTL responses to HIV-1 and EIAV
demonstrated that Gag proteins were recognized by
CTL from the most individuals. HIV-1 subtype C
isolates had low aa diversity in Gag CA protein, and
infected patients had an immunodominant CTL response
to this protein (Novitsky et al., 2002). Analysis of CTL
recognition of EIAV proteins using retroviral vectors
expressing Gag p9, p11, p15 (MA), p26 (CA), Pol, SU,
TM, Tat, Rev, and S2 found that CTL recognition of
Gag MA and CA proteins was most frequent (McGuire
et al., 2000). Gag MA and CA proteins were recognized
by CTL from 100% to 86% of seven EIAV-infected
horses, respectively. The results suggested that the 359
aa comprising MA and CA proteins were capable of
stimulating CTL in most horses, although these results
need to be confirmed using horses with defined differ-
ences in MHC class I alleles. A previous study dissec-
ting CTL responses from five EIAV-infected horses
found recognition of overlapping peptides in EIAV Gag
indicating a possible EC in the MA protein and another
in the CA protein; however, the horses had limited
diversity of MHC class I haplotypes (Zhang et al.,
1998).
In this study, horses with heterologous MHC class I
alleles defined by sequence-based typing were used to
rigorously test the hypothesis that CTL from EIAV-infected
horses with diverse MHC class I alleles recognize EC inEC recognized
Virus stimulation EC peptide stimulation
2, 3 2, 3, 4
2 2
3 1, 3
2, 3 2, 3
2, 4 2, 4
3 2, 3, 4
4 4
b 1, 2 1, 2, 3
1 1, 2, 3, 4
1 1
1, 3 Not done
1 Not done
1, 3 Not done
1, 2 Not done
4 Not done
None None
None None
.
cytes from this horse.
(Zhang et al., 1998).
Table 3
EIAV Gag CA protein synthetic peptides used for EC identification
Pool Amino acid sequence Peptide name
P3 PIMIDGAGNRNFRPL P3-1
DGAGNRNFRPLTPRG P3-2
NRNFRPLTPRGYTTW P3-3
RPLTPRGYTTWVNTI P3-4
PRGYTTWVNTIQTNG P3-5
TTWVNTIQTNGLLNE P3-6
NTIQTNGLLNEASQN P3-7
C. Chung et al. / Virology 327 (2004) 144–154146Gag MA and CA proteins. Additionally, the use of CTL
from 17 EIAV-infected carrier horses enhanced the
probability of identifying EC involved in virus control.
Four EC were identified and three of these were
recognized by 50% or more infected horses in a subset
with diverse MHC class I alleles. The identification of
these EC will allow preparation of small polypeptide
antigens containing multiple CTL epitopes for evaluation
in outbred horses.
TNGLLNEASQNLFGI P3-8
LNEASQNLFGILSVD P3-9
SQNLFGILSVDCTSE P3-10
FGILSVDCTSEEMNA P3-11
P4 SVDCTSEEMNAFLDV P4-1
TSEEMNAFLDVVPGQ P4-2
MNAFLDVVPGQAGQK P4-3
LDVVPGQAGQKQILL P4-4
PGQAGQKQILLDAID P4-5
GQKQILLDAIDKIAD P4-6
ILLDAIDKIADDWDN P4-7
AIDKIADDWDNRHPL P4-8
IADDWDNRHPLPNAP P4-9
WDNRHPLPNAPLVAP P4-10
HPLPNAPLVAPPQGP P4-11
P5 NAPLVAPPQGPIPMT P5-1
VAPPQGPIPMTARFI P5-2
QGPIPMTARFIRGLG P5-3
PMTARFIRGLGVPRE P5-4
RFIRGLGVPRERQME P5-5
GLGVPRERQMEPAFD P5-6
PRERQMEPAFDQFRQ P5-7
QMEPAFDQFRQTYRQ P5-8Results
CTL from EIAV-infected horses recognize Gag EC
To identify EC, CTL from 17 EIAV-infected horses
(Table 1) were evaluated. Peptide mapping of CTL from
12 horses was done in this study and data were used from
five other horses in a previous publication (Zhang et al.,
1998). CTL recognition of peptides was assessed using EK
target cells pulsed with seven pools of MA and CA
peptides. These peptides were 15–16 aa long and over-
lapped by 11–12 aa (Tables 2 and 3). Effectors were
PBMC from EIAV-infected horses stimulated with
EIAVWSU5. Fig. 1 contains peptide-mapping data derived
with CTL from horse H596 that was representative of data
from the other horses. The initial mapping with larger
peptide pools (Fig. 1A) was followed by a second mappingTable 2
EIAV Gag MA protein synthetic peptides used for EC identification
Pool Amino acid sequence Peptide name
P1 MGDPLTWSKALKKLE P1-1
LTWSKALKKLEKVTV P1-2
KALKKLEKVTVQGSQ P1-3
KLEKVTVQGSQKLTT P1-4
VTVQGSQKLTTGNCN P1-5
GSQKLTTGNCNWALS P1-6
LTTGNCNWALSLVDL P1-7
NCNWALSLVDLFHDT P1-8
ALSLVDLFHDTNFVK P1-9
VDLFHDTNFVKEKDW P1-10
HDTNFVKEKDWQLRD P1-11
FVKEKDWQLRDVIPL P1-12
KDWQLRDVIPLLEDV P1-13
LRDVIPLLEDVTQTL P1-14
P2 IPLLEDVTQTLSGQE P2-1
EDVTQTLSGQEREAF P2-2
QTLSGQEREAFERTW P2-3
GQEREAFERTWWAIS P2-4
EAFERTWWAISAVKM P2-5
RTWWAISAVKMGLQI P2-6
AISAVKMGLQINNVV P2-7
VKMGLQINNVVDGKA P2-8
LQINNVVDGKASFQL P2-9
NVVDGKASFQLLRAK P2-10
GKASFQLLRAKYEKK P2-11
FQLLRAKYEKKTANK P2-12
RAKYEKKTANKKQSE P2-13
EKKTANKKQSEPSEEY P2-14
AFDQFRQTYRQWIIE P5-9
FRQTYRQWIIEAMSE P5-10
P6 YRQWIIEAMSEGIKV P6-1
IIEAMSEGIKVMIGK P6-2
MSEGIKVMIGKPKAQ P6-3
GIKVMIGKPKAQNIRQ P6-4
MIGKPKAQNIRQGAKE P6-5
PKAQNIRQGAKEPYPE P6-6
NIRQGAKEPYPEFVDR P6-7
GAKEPYPEFVDRLLSQ P6-8
PYPEFVDRLLSQIKSE P6-9
FVDRLLSQIKSEGHPQ P6-10
LLSQIKSEGHPQEISK P6-11
IKSEGHPQEISKFLTD P6-12
P7 GHPQEISKFLTDTLTI P7-1
EISKFLTDTLTIQNAN P7-2
FLTDTLTIQNANEECR P7-3
TLTIQNANEECRNAMR P7-4
QNANEECRNAMRHLRP P7-5
EECRNAMRHLRPEDTL P7-6
NAMRHLRPEDTLEEKM P7-7
HLRPEDTLEEKMYACR P7-8
EDTLEEKMYACRDIGT P7-9
EEKMYACRDIGTTKQK P7-10
YACRDIGTTKQKMMLL P7-11
DIGTTKQKMMLLAKAL P7-12with pools of two peptides (Fig. 1B) and a third mapping
with individual peptides (Fig. 1C). It was found that CTL
from 16 of 17 horses recognized at least one peptide from
Gag MA and CA proteins (Fig. 2). The exception was
PBMC from horse A2153 that did not recognize any of the
Fig. 1. Identification of peptides containing CTL epitopes. PBMC from
EIAV-infected horse H596 were stimulated with EIAVWSU5 and evaluated.
Target cells were pulsed first with peptide pools (A), then with two peptides
(B), and finally with individual peptides (C). Asterisks on top of columns
indicate a % specific lysis that was significantly different (defined in
Materials and methods) from target cells with no peptide (NP). The error
bars on the columns are 1 SE.
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identification of four EC based on regions with the most
peptides recognized by CTL from the most horses. These
were designated EC1–4 by their position in the linear
sequence of Gag MA and CA proteins (Fig. 2).
EC1 was 35 aa including MA 1–35 and was recognized
by CTL from 7 of the total 17 horses (Fig. 2). MA 77–119
(43 aa), designated EC2, was recognized by CTL from six
horses. CA 156–187 (32 aa), designated EC3, was also
recognized by CTL from six horses. Finally, CA 192–232(41 aa), designated EC4, was recognized by CTL from
seven horses. Horse H540 had CTL that recognized peptides
in a non-EC region, but not in an EC. EIAV-stimulated
PBMC from horse A2153 did not recognize either EC or
other MA or CA peptides as indicated above. The remaining
15 horses had CTL to Gag MA and CA proteins that
recognized one or more of the identified EC.
Expansion of EC1–4 recognition by stimulation of CTL with
EC peptide pools
Once EC1–4 were identified using CTL stimulated with
EIAVWSU5, it was of interest to determine if CTL sti-
mulation with EC peptides would result in expanded EC1–4
recognition. PBMC from all but the five horses (H507,
H513, 521, H529, and H532) used for CTL epitope
mapping in a previous study (Zhang et al., 1998) were
available for stimulation with each of four peptide pools
containing peptides from each EC. PBMC stimulated with a
particular EC peptide pool were tested on targets pulsed
with the same EC peptide pool. There was still no EC
recognition by stimulated PBMC from horses H540 and
A2153; however, five horses had CTL that recognized
additional EC. CTL from four of these horses including
H593, H614, H631, and A2147 recognized from one to two
additional EC that were not recognized in mapping with
EIAVWSU5-stimulated PBMC (Table 1, compare last two
columns). CTL from A2140 recognized three additional EC
(Table 1).
EC recognition by EIAV-infected horses with diverse MHC
class I alleles
To determine if EC were recognized by horses with
diverse MHC class I alleles, a subset of horses from Table 1
was evaluated. This subset consisted of the first eight horses
listed in Table 1 because these horses had unique MHC class
I alleles in comparison to the remaining horses. MHC class I
alleles were determined by sequence-based typing except
for H629, which had a different ELA-A type. In a previous
study, horses with different ELA-A haplotypes did not share
alleles by sequence-based typing (Chung et al., 2003). CTL
from A2147 and H596, which shared an ELA-A4 hap-
lotype, but did not share the same MHC class I alleles
determined by sequencing, both recognized peptides P6-9
and P6-10 in EC3 (Fig. 2). However, fine mapping
demonstrated that CTL from H596 and A2147 did not
recognize the same optimal epitopes within peptides P6-9
and P6-10 (Table 4), confirming that the different alleles in
these two horses presented different peptides.
When EC recognition by the eight horses with unique
MHC class I alleles were considered, two recognized EC1,
six recognized EC2, five recognized EC3, and four
recognized EC4 (Table 5). Therefore, three of the four EC
were broadly recognized by CTL from horses with diverse
MHC class I alleles, with 50% or more of these horses
Fig. 2. Gag MA (A) and CA (B) peptides recognized by CTL from EIAV-infected horses. All peptides recognized by CTL from horses H507, H513, H521,
H529 and H540 are from a previous study (Zhang et al., 1998), whereas the remaining peptides are from this study. EC1–4 is shadowed. Epitope-lacking
regions are shadowed and boxed. Peptide sequences and horse numbers in boxes indicate fine-mapped epitopes. The underlined peptides were recognized by
CTL from eight horses with unique MHC class I alleles.
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Table 4
Optimal epitopes in P6-9 and P6-10 peptides recognized by CTL from
horses H596 and A2147
Peptides % Specific killing in
51Cr release assay
H596 CTL A2147 CTL
PYPEFVDRLLSQIKSE (P6-9) 25 9
YPEFVDRLLS NSa 31
FVDRLLSQI 39 NS
FVDRLLSQIKSEGHPQ (P6-10) 29 9
FVDRLLSQIK 36 NS
RLLSQIKSEG NS 30
a NS indicates no significant % specific lysis.
Table 5
Summary of EC recognition by CTL from eight EIAV-infected horses with
unique MHC class I allelesa
EC Peptide and no. of aa Horses with CTL
to each EC (%)
1 MA 1–35, 35 aa H593, H631 (25%)
2 MA 77–119, 43 aa A2147, A2150, H596,
H610, H614, H631 (75%)
3 CA156–187, 32 aa A2147, H593, H596,
H614, H631 (62.5%)
4 CA 192–232, 41 aa A2147, H610, H614, H629 (50%)
a The eight horses with unique MHC class I alleles are the first eight horses
listed in Table 1.
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hypothesis that CTL from EIAV-infected horses with diverse
MHC class I alleles would recognize Gag EC was accepted.
Analysis of aa sequence variability within EC1–4 and two
epitope-lacking regions
To evaluate the aa sequence variability of EC1–4, all 79
complete EIAV Gag MA and CA sequences from GenBank
containing Wyoming, Idaho, Texas, UK, PV, WSU5, and
Japan strains, and their variants were analyzed after multiple
alignment. Analysis of these available sequences was done
to provide a minimum estimate of variability of the
identified EC. EC1 had nine variant sequences among the
79 sequences, whereas EC2 had 15, EC3 had 11, and EC4
had 8 (Fig. 3). EC2 also had the largest number of changed
aa with substitutions or deletions occurring in 20 of 43
residues (47%). EC4 had 15 residues with change (37%),
EC1 had 9, (26%) and EC3 had 8 (25%). This was in
comparison to epitope-lacking region1 and region2 with six
(17%) residue changes each (Fig. 3). The overall percentage
of aa residues with change was 30% for Gag MA and CA
proteins. Therefore, EC2, which was recognized by CTL
from the most horses with diverse MHC class I alleles, was
the most variable EC. This region may have less functional
importance, thereby allowing for more variation. Further,
both epitope-lacking regions as well as EC1 and EC3 had
fewer aa residues with changes than the overall sequence,
suggesting more constraint on variation in these regions.
Comparison between EC recognition and control of disease
As a preliminary analysis to determine whether CTL
responses to specific EC might be related with control of
EIAV, days since the last clinical episode in the eight horses
with unique MHC class I alleles were compared with the
recognition of specific EC by CTL (Table 6). From this
analysis, horses with CTL responses to EC4 were signifi-
cantly more likely to have a fewer number of days since the
last clinical episode (P = 0.03) than horses with CTL
responses to other EC. In contrast, there was no significant
relationship between days postinfection and EC recognition.The reason for a significant relationship between CTL
responses to EC4 and fewer days since the last clinical
episode is not known. It was surprising since the horses
analyzed were infected with two different virus strains at
different times and likely had different immune responses.
However, the observation could be important and needs
conformation with additional horses.Discussion
Viral antigenic variation and host MHC class I poly-
morphism are the main barriers to inducing protective CTL
responses against lentiviruses in humans and other outbred
animals. One possible solution is to immunize with EC that
are recognized by CTL from individuals with diverse MHC
class I alleles (Buseyne et al., 1993; Goulder et al., 2000a;
Yusim et al., 2002). This approach to vaccine design could
include expressing EC in DNA plasmids or other vectors.
There are several advantages to using smaller EC peptides
instead of whole proteins to induce CTL. One is that there is
a marked increase in peptide-MHC class I formation and
killing of target cells expressing CTL epitopes from
minigenes compared to expression of the whole protein
suggesting that similar events occur in APC (Anton et al.,
1997). Immunization with EC could also exclude regions of
full-length proteins that induce dominant, but ineffective or
adverse immune responses (Raabe et al., 1998; Wang et al.,
1994; Woodberry et al., 1999). Additionally, the EC contain
adjacent natural aa for epitope processing. Finally, several
variant EC could be included in a vaccine construct.
CTL responses to Gag MA and CA could be a
mechanism for controlling clinical disease episodes in
naturally occurring lentiviral infections including EIAV.
CTL from EIAV-infected horses with limited diversity of
MHC class I haplotypes recognized Gag MA and CA
proteins more frequently than other viral proteins (McGuire
et al., 2000). Gag MA and CA in EIAV are the most
abundant proteins, reaching 58% of total EIAV proteins, and
are more conserved than other EIAV proteins including Env
and Pol (Montelaro et al., 1993). Similarly, the CTL
response to HIV-1 Gag proteins are more immunodominant
Fig. 3. Amino acid sequence variation of EC1–4 in 79 EIAV proviral clones and plasma virus variants from GenBank. Only variable sequences are presented
with the dots indicating aa identical to those in EIAVWSU5 and the dashes indicating amino acid deletions.
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Table 6
EC recognition by CTL from horses with unique MHC class I alleles and
control of clinical disease episode
Horse no. Infection history EC recognized
Days postinfection Days since the
last clinical disease
A2147 1158 209 2, 3, 4
A2150 1158 574 2
H593 1442 780 1, 3
H596 626 437 2, 3
H610 490 120 2, 4
H614 626 161 2, 3, 4
H629 317 177 4
H631 483 358 1, 2, 3
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significantly more IFN-gamma-secreting CD8+ T lympho-
cytes to HIV-1 Gag CA protein than to any other proteins
(Novitsky et al., 2002). A study of HIV-1 Gag CTL
responses in Caucasoid and African Americans infected
with HIV-1 clade B as well as African adults and children in
South Africa infected with clade C found three immunodo-
minant regions in MA and CA proteins (Goulder et al.,
2000a). Although the immunogenicity of these regions is
partly explained by the clustering of similar or identical
epitopes between clades, it generally reflects the predom-
inance of HLA-A2- and -A3-restricted Gag MA-specific
responses in Caucasoids and HLA-B42- and -B81-restricted
CA-specific responses in Africans (Goulder et al., 2000a;
Novitsky et al., 2002). Nevertheless, the data suggest that
CTL EC occur in lentivirus Gag and indicate a need for
more data from experimental groups with diverse MHC
class I alleles. The goal of this study was to identify EC in
EIAV Gag MA and CA proteins that could eventually be
used to induce CTL in horses with diverse MHC class I
alleles. Assuming that the CTL responses to MA and CA
epitopes are important in the control of EIAV infection, CTL
from horses that had controlled disease episodes for more
than 120 days were used to identify EC in these proteins.
Then, recognition of EC by CTL from horses with unique
MHC class I alleles was evaluated.
Seventeen horses with EIAV infection were used for
initial identification of EC. Gag MA, CA proteins, or both
were recognized by CTL from all but one horse and the
peptides recognized were in four clusters (EC1–4). One or
more of these EC were recognized by CTL from 15 of the
horses, whereas one other horse had CTL recognizing Gag
peptides outside the EC. However, it was not possible to
identify a universal EC recognized by CTL from all the
responding horses. The two horses (A2153 and H540) that
did not have CTL to EC were evaluated for CTL to Gag
epitopes early in infection in previous studies (Mealey et al.,
2003; Zhang et al., 1998). No CTL to Gag epitopes were
detected in A2153 PBMC soon after infection with
EIAVWSU5 (Mealey et al., 2003) and none were found later
in infection in the current study. H540 responded to one CA
peptide outside the defined EC early after infectionEIAVWSU5 (Zhang et al., 1998), but had no response to EC
peptides in either that study or the current study. Failure of
these two horses to make CTL to EC peptides either early or
late after infection suggests that the lack of response was
because of haplotype or other factors affecting immunodo-
minance rather than sequence variation. The identification of
EC1–4 and the availability of eight EIAV-infected horses
with unique MHC class I alleles allowed us to test the
hypothesis that CTL from EIAV-infected horses with diverse
MHC class I alleles recognize EC in Gag MA and CA
proteins. Three of the four EC were recognized by CTL from
50% or more of eight horses with diverse MHC class I alleles
and the hypothesis was accepted. This broad CTL recog-
nition of EIAV EC exceeds that of the major EC in HIV-1
Gag MA and CA proteins, which was recognized by CTL
from 39% of a test group that included two predominant
HLA-A types (Goulder et al., 2000a). Whether the broad EC
recognition by CTL from these horses will extend to larger
groups of horses will have to be tested.
Gag has been generally considered a highly conserved
lentiviral protein; however, three of five immunodominant
regions identified in HIV-1C Gag CA protein were less
variable than overall Gag MA suggesting different func-
tional and immunological pressures in different Gag regions
(Novitsky et al., 2002). Likewise, EIAV Gag sequences vary
among strains as shown in EIAVID which had 12% aa
differences from some other EIAV strains including
EIAVWSU5 (Zhang et al., 1999). The minimum variability
of the identified EC and non-EC regions was analyzed in the
79 available sequences from GenBank which included
sequences from at least seven different EIAV strains and
their variants. The overall percentage of EIAV Gag MA and
CA aa positions with changes was 30%, whereas EC1
(26%) and EC3 (25%) had fewer aa residue changes than
the overall proteins and EC2 (47%) and EC4 (37%) had
more changes. The relative conservation of EIAV Gag EC1
and EC3 sequences could be related to their involvement in
the function of MA and CA, respectively, as sequences
essential for virus function have less variation and therefore
lower probability of immune escape (Goulder et al., 1997;
Kelleher et al., 2001; Wagner et al., 1999; Walker and
Korber, 2001). For instance, EIAV MA aa 11–19 in EC1
contains a leucine-rich nuclear export signal (Hatanaka et
al., 2002), which is similar to the location of a nuclear
export signal in HIV-1 MA (Dupont et al., 1999), and this
may constrain the amount of variation. Interestingly, CTL
from each of seven horses responding to EC1 recognized
only one EC1 epitope, but most horses with CTL recogniz-
ing the more variable EC4 recognized multiple EC4
epitopes (Fig. 2). Further, a significant relationship between
fewer days since the last clinical episode and horses with
CTL to EC4 could be due to CTL escape variants in this
region. Finding this relationship was surprising since the
horses analyzed were infected with two different virus
strains at different times and likely had different immune
responses.
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identified using CTL from EIAV-infected horses. Three of
these (EC2–4) were recognized by CTL from more than
50% of eight horses with unique MHC class I alleles. These
EC, which include the more conserved EC3, will be further
evaluated to determine which have more high avidity CTL
epitopes because immunization with such epitopes may be a
way to overcome both MHC class I diversity and viral
variation.Materials and methods
EIAV infection of horses
A total of 17 EIAV-infected horses were used in this
study (Table 1). Seven horses were infected with 107 50%
tissue culture infective doses (TCID50) of EIAVWSU5
injected intravenously. These included horses H593 and
H631, and previously infected horses H540 (Zhang et al.,
1998), A2140, A2147, A2150, and A2153 (Mealey et al.,
2001). Another five horses including H596, H601, H610,
H614 and H629 were infected with 300 TCID50 of EIAVPV.
The origin of EIAVPV has been described (Rwambo et al.,
1990b). EIAVWSU5 (GenBank accession no. NP_056901)
and EIAVPV (GenBank accession no. AAC03760) have
identical Gag MA and CA protein sequences allowing the
use of horses infected with both strains for EC identifica-
tion. Finally, published epitope mapping data (Zhang et al.,
1998) using another five horses infected with EIAVWSU5
(H507, H513, H521, H529, H532) were used to identify EC.
Autologous EK cells for CTL targets were obtained from
kidney biopsies before infection of each horse (McGuire et
al., 1994) and maintained as frozen cell lines. Before use in
CTL studies, all the horses were free of clinical disease for
at least 3 months determined by measuring body temper-
ature daily and counting platelets weekly.
Evaluation of MHC class I haplotypes
Nine of the horses listed in Table 1 were evaluated by
sequencing RT-PCR products of MHC class I alleles
amplified with classical MHC class I-specific primers
(Chung et al., 2003). The MHC class I ELA-A haplotypes
of all 17 horses were determined by lymphocyte micro-
cytotoxicity (Table 1) using antisera A1-A10 and W11
(Bailey, 1980). The ELA-A haplotypes are associated with a
putative ELA-A locus (Bailey et al., 2000; Bernoco et al.,
1987; Lazary et al., 1988).
PBMC isolation and stimulation of memory CTL
PBMC were isolated from the EIAV-infected horses by
centrifugation on Histopaque (specific gravity 1.077),
washed four times, and viability determined (Wyatt et al.,
1988). Monocytes in PBMC were infected with EIAVWSU5at a multiplicity of infection of one or incubated with
peptides (103 nM) in 5 ml of RPMI 1640 with 20% FBS at
37 8C for 2 h with gentle mixing every 15 min (McGuire et
al., 2000; Zhang et al., 1998). Stimulations were done in a
175 cm2 tissue culture flask containing RPMI 1640 with
10% FCS, 5  105 M 2-mercaptoethanol, and 20 mM
Hepes. After incubation in a humidified chamber with 5%
CO2 at 37 8C for 7 days, viable lymphocytes were counted
using trypan blue dye exclusion in a hemocytometer for use
in the 51Cr release assay (McGuire et al., 2000).
Synthetic peptides of EIAV Gag MA and CA proteins
Fifty-two peptides of 15 aa overlapping by 11 aa and 21
peptides of 16 aa overlapping by 12 aa with C-terminal OH
and N-terminal H groups were synthesized to cover the
entire EIAVWSU5 Gag MA and CA proteins (Sigma-
Genosys, The Woodlands, TX) (Tables 1 and 2). The
peptides were dissolved in 100% dimethyl sulfoxide and
stored in 20 8C before dilution for use in CTL mapping to
identify EC.
CTL assay
The 51Cr-release assay was used to identify EC recognized
by CTL from EIAV-infected horses. EK target cells (3 104/
well) were incubated in collagen-coated wells of 96-well
plates at 37 8Cwith 5% CO2 for 24 h before
51Cr labeling and
peptide pulsing. These cells were pulsed with 104 nM
synthetic peptides in 50 Al/well of DMEM containing 5%
FBS and 1.25 ACi of 51Cr at 37 8C for 2 h and then washed
three times with DMEM. Effectors (effector-to-target cell
ratio of 50:1) were incubated with target cells in 200 Al/well
RPMI containing 10% FBS at 37 8C with 5% CO2 for 17 h
(McGuire et al., 1994), and then 100 Al of supernatant
removed from each well to determine 51Cr release. Percent
specific lysis was calculated as [(E  S) / (M  S)]  100,
where E was the mean of three test wells, S was the mean
spontaneous release from three wells without effector cells,
and M was the mean maximal release from three wells with
2% Triton X-100 (Siliciano et al., 1985). The standard error
(SE) of % specific lysis was calculated taking into consid-
eration the variability of E, S, andM as described previously
(Siliciano et al., 1985). Only assays with a spontaneous lysis
of b30% were used. Specific lysis of peptide-pulsed target
cells that was N5% and exceeded lysis of nonpulsed target
cells by N2.5 SE was considered significant.
Peptide mapping to identify EC
Initial peptide mapping used seven peptide pools, each
containing 10–14 synthetic peptides each with a final
concentration of 104 nM, to pulse target cells. A second
mapping used pools of two peptides and a final mapping
used individual peptides. Regions with the most peptides
identified by CTL from the most horses were designated as
C. Chung et al. / Virology 327 (2004) 144–154 153EC. Epitope-lacking regions were defined as MA or CA
regions without recognition by CTL from EIAV-infected
horses in this and a previous study (Zhang et al., 1998).
Analysis of aa sequence variability in EC
Query sequence EIAVWSU5 Gag MA and CA had 79
blast hits in GenBank. Fifteen sequences were Wyoming
strain and its variants, 16 were Idaho strain and its variants,
30 were WSU5 strain and its variants, and seven were Texas
strain and its variants. The others were two Japan strains,
UK, PV, their variants, and seven unknown strains. Those
sequences were compared using a multiple alignment
program. The variabilities of EC1–4 and in epitope-lacking
regions1 and region2 were calculated as the total number of
aa residues with changes.
Statistical analysis
The relationship between CTL to specific EC and days
postinfection or days since the last clinical episode was
evaluated by analysis of contingency tables based on the
Fisher’s exact test using GraphPad InStat version 3.05
(GraphPad Software, Inc., San Diego, CA). Significance
was determined by P b 0.05.Acknowledgments
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